Evidence map›Paper›PMID 28840857›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2018

Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.

Stephanie L Skala, Hong Xiao, Aaron M Udager, Saravana M Dhanasekaran, Sudhanshu Shukla, Yang Zhang, Carrie Landau, Lina Shao, Diane Roulston, Lisha Wang and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Guideline
  2. Guideline
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Renal Cell Carcinoma of Variant Histology: Biology and Therapies.Hematology/oncology clinics of North America · 2023
    Review
  13. Article
  14. TFEB: a double-edged sword for tumor metastasis.Journal of molecular medicine (Berlin, Germany) · 2023
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Stephanie L SkalaDepartment of Pathology, University of Michigan Health System, Ann Arbor, MI, USA.
Hong XiaoDepartment of Pathology, University of Michigan Health System, Ann Arbor, MI, USA.
Aaron M UdagerDepartment of Pathology, University of Michigan Health System, Ann Arbor, MI, USA.ORCID 0000-0002-8254-5404
Saravana M DhanasekaranMichigan Center for Translational Pathology, Ann Arbor, MI, USA.
Sudhanshu ShuklaMichigan Center for Translational Pathology, Ann Arbor, MI, USA.
Yang ZhangClinical Cytogenetics Laboratory, University of Michigan Health System, Ann Arbor, MI,USA.
Carrie LandauClinical Cytogenetics Laboratory, University of Michigan Health System, Ann Arbor, MI,USA.
Lina ShaoDepartment of Pathology, University of Michigan Health System, Ann Arbor, MI, USA.
Diane RoulstonDepartment of Pathology, University of Michigan Health System, Ann Arbor, MI, USA.
Lisha WangMichigan Center for Translational Pathology, Ann Arbor, MI, USA.
Javed SiddiquiMichigan Center for Translational Pathology, Ann Arbor, MI, USA.
Xuhong CaoMichigan Center for Translational Pathology, Ann Arbor, MI, USA.
Cristina Magi-GalluzziPathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
Miao ZhangUniversity of Texas-MD Anderson Cancer Center, Houston, TX, USA.
Adeboye O OsunkoyaDepartments of Pathology and Urology, Emory University School of Medicine, Atlanta, GA, USA.
Steven C SmithVirginia Commonwealth University School of Medicine, Richmond, VA, USA.ORCID 0000-0003-0982-4607
Jesse K McKenneyPathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.
Bryan L BetzDepartment of Pathology, University of Michigan Health System, Ann Arbor, MI, USA.
Jeffrey L MyersDepartment of Pathology, University of Michigan Health System, Ann Arbor, MI, USA.
Arul M ChinnaiyanDepartment of Pathology, University of Michigan Health System, Ann Arbor, MI, USA.
Scott A TomlinsDepartment of Pathology, University of Michigan Health System, Ann Arbor, MI, USA.
Rohit MehraDepartment of Pathology, University of Michigan Health System, Ann Arbor, MI, USA.

Funding

Howard Hughes Medical Institute
6 · The paper itself

Abstract

Renal cell carcinomas with MITF aberrations demonstrate a wide morphologic spectrum, highlighting the need to consider these entities within the differential diagnosis of renal tumors encountered in clinical practice. Herein, we describe our experience with application of clinical fluorescence in situ hybridization (FISH) assays for detection of TFE3 and TFEB gene aberrations from 85 consecutive renal cell carcinoma cases submitted to our genitourinary FISH service. Results from 170 FISH assays performed on these tumors were correlated with available clinicopathologic findings. Ninety-eight percent of renal tumors submitted for FISH evaluation were from adult patients. Thirty-one (37%) tumors were confirmed to demonstrate MITF aberrations (21 TFE3 translocation, 4 TFEB translocation, and 6 TFEB amplification cases). Overall, renal cell carcinomas with MITF aberrations demonstrated morphologic features overlapping with clear cell, papillary, or clear cell papillary renal cell carcinomas. Renal cell carcinomas with MITF aberrations were significantly more likely to demonstrate dual (eosinophilic and clear) cytoplasmic tones (P=0.030), biphasic TFEB translocation renal cell carcinoma-like morphology (P=0.002), psammomatous calcifications (P=0.002), and nuclear pseudoinclusions (P=0.001) than renal cell carcinomas without MITF aberrations. Notably, 7/9 (78%) renal cell carcinomas exhibiting subnuclear clearing and linear nuclear array (6 of which showed high World Health Organization/International Society of Urological Pathology nucleolar grade) demonstrated TFE3 translocation, an association that was statistically significant when compared with renal cell carcinomas without MITF aberrations (P=0.009). In this cohort comprising consecutive cases, TFEB-amplified renal cell carcinomas were more commonly identified than renal cell carcinomas with TFEB translocations, and four (67%) of these previously unreported TFEB-amplified renal cell carcinomas demonstrated oncocytic and papillary features with a high World Health Organization/International Society of Urological Pathology nucleolar grade. In summary, TFE3 and TFEB FISH evaluation aids in identification and accurate classification of renal cell carcinomas with MITF aberrations, including TFEB-amplified renal cell carcinoma, which may demonstrate aggressive behavior.

Indexed as

AdolescentAdultAgedAged, 80 and overBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBiomarkers, TumorCarcinoma, Renal CellChildFemaleGene AmplificationHumansIn Situ Hybridization, FluorescenceKidney NeoplasmsMaleMicrophthalmia-Associated Transcription FactorMiddle AgedBasic Helix-Loop-Helix Leucine Zipper Transcription FactorsBiomarkers, TumorMicrophthalmia-Associated Transcription FactorMITF protein, humanTFE3 protein, humanTFEB protein, human

Identifiers

PMID28840857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.